Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1a/b study of RLBN1127 for treatment of NASH

Trial Profile

A phase 1a/b study of RLBN1127 for treatment of NASH

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACQT 1127 (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Sponsors Acquist Therapeutics
  • Most Recent Events

    • 03 Oct 2018 New trial record
    • 02 Oct 2018 According to an Acquist Therapeutics media release, data from this study will be presented at the annual meeting of the American College of Rheumatology (ACR) (Oct 2018).
    • 25 Sep 2018 According to an Acquist Therapeutics media release, update scientific findings and clinical development plans for its drug candidates in two diseases, nonalcoholic steatohepatitis (NASH) and gout will be present at the BIO Investor Forum (Oct 2018) .
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top